Header Logo

Connection

William Towner to HIV Infections

Back to Details
This is a "connection" page, showing publications William Towner has written about HIV Infections.
William Towner
Connection Strength
4.226
HIV Infections
  1. Effect of an Electronic Alert on Targeted HIV Testing Among High-Risk Populations. Perm J. 2018; 22:18-015.
    View in: PubMed
    Score: 0.388
  2. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
    View in: PubMed
    Score: 0.265
  3. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):614-8.
    View in: PubMed
    Score: 0.227
  4. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther. 2010; 15(6):803-16.
    View in: PubMed
    Score: 0.223
  5. Trends and correlates of HIV testing during pregnancy in racially/ethnically diverse insured population, 1997-2006. Matern Child Health J. 2009 Sep; 13(5):633-40.
    View in: PubMed
    Score: 0.203
  6. Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems. J Acquir Immune Defic Syndr. 2023 12 01; 94(4):341-348.
    View in: PubMed
    Score: 0.146
  7. Variation in Heart Failure Risk by HIV Severity and Sex in People With HIV Infection. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):175-181.
    View in: PubMed
    Score: 0.135
  8. Project SLIP: Implementation of a PrEP Screening and Linkage Intervention in Primary Care. AIDS Behav. 2021 Aug; 25(8):2348-2357.
    View in: PubMed
    Score: 0.121
  9. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Netw Open. 2020 06 01; 3(6):e207954.
    View in: PubMed
    Score: 0.115
  10. Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system. HIV Clin Trials. 2018 10; 19(5):177-187.
    View in: PubMed
    Score: 0.103
  11. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials. 2017 05; 18(3):118-125.
    View in: PubMed
    Score: 0.093
  12. Examining HIV Viral Load in a Matched Cohort of HIV Positive Individuals With and Without Psoriasis. J Drugs Dermatol. 2017 Apr 01; 16(4):372-377.
    View in: PubMed
    Score: 0.092
  13. Invasive Pneumococcal Disease Among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System. AIDS Patient Care STDS. 2016 10; 30(10):463-470.
    View in: PubMed
    Score: 0.089
  14. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. J Acquir Immune Defic Syndr. 2016 09 01; 73(1):39-46.
    View in: PubMed
    Score: 0.088
  15. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):413-9.
    View in: PubMed
    Score: 0.086
  16. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
    View in: PubMed
    Score: 0.083
  17. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):705-13.
    View in: PubMed
    Score: 0.082
  18. Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. AIDS Patient Care STDS. 2015 Jul; 29(7):370-8.
    View in: PubMed
    Score: 0.081
  19. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1167-73.
    View in: PubMed
    Score: 0.080
  20. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015 Apr 15; 60(8):1278-80.
    View in: PubMed
    Score: 0.079
  21. HIV infection and incidence of ischemic stroke. AIDS. 2014 Aug 24; 28(13):1911-9.
    View in: PubMed
    Score: 0.077
  22. Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr. 2014 Aug 15; 66(5):495-502.
    View in: PubMed
    Score: 0.077
  23. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014 Apr 24; 28(7):989-97.
    View in: PubMed
    Score: 0.075
  24. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials. 2014 Mar-Apr; 15(2):51-6.
    View in: PubMed
    Score: 0.074
  25. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):160-6.
    View in: PubMed
    Score: 0.074
  26. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014 Jan; 69(1):12-20.
    View in: PubMed
    Score: 0.071
  27. Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012 Jun 01; 60(2):183-90.
    View in: PubMed
    Score: 0.066
  28. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012 Dec; 28(12):1630-6.
    View in: PubMed
    Score: 0.065
  29. Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012 May; 56(5):2305-13.
    View in: PubMed
    Score: 0.064
  30. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
    View in: PubMed
    Score: 0.063
  31. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS. 2011 Sep 10; 25(14):1771-7.
    View in: PubMed
    Score: 0.063
  32. Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California. AIDS Patient Care STDS. 2011 Sep; 25(9):525-32.
    View in: PubMed
    Score: 0.062
  33. HIV quality performance measures in a large integrated health care system. AIDS Patient Care STDS. 2011 Jan; 25(1):21-8.
    View in: PubMed
    Score: 0.060
  34. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010 Jul 17; 24(11):1765-70.
    View in: PubMed
    Score: 0.058
  35. A review of the safety and tolerability profile of the next-generation NNRTI etravirine. AIDS Res Hum Retroviruses. 2010 Jul; 26(7):725-33.
    View in: PubMed
    Score: 0.058
  36. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):62-9.
    View in: PubMed
    Score: 0.056
  37. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010; 15(7):1045-52.
    View in: PubMed
    Score: 0.056
  38. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009 Nov 13; 23(17):2337-45.
    View in: PubMed
    Score: 0.055
  39. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
    View in: PubMed
    Score: 0.051
  40. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study. HIV Clin Trials. 2008 May-Jun; 9(3):152-63.
    View in: PubMed
    Score: 0.050
  41. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
    View in: PubMed
    Score: 0.049
  42. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):39-48.
    View in: PubMed
    Score: 0.047
  43. Perceptions of human immunodeficiency virus testing services among HIV-positive persons not in medical care. Sex Transm Dis. 2006 Jul; 33(7):464; author reply 465.
    View in: PubMed
    Score: 0.044
  44. Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America. AIDS Patient Care STDS. 2003 Jun; 17(6):267-75.
    View in: PubMed
    Score: 0.035

© 2024 Kaiser Permanente